# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
In the September 9 cover article of Cancer Cell, researchers integrated 10x single cell and spatial technologies to identify a ...
Stephens & Co. analyst Mason Carrico reiterates 10x Genomics (NASDAQ:TXG) with a Overweight and maintains $30 price target.
Leerink Partners analyst Mike Kratky initiates coverage on 10x Genomics (NASDAQ:TXG) with a Outperform rating and announces ...
Gold rally loses momentum as dollar rebounds and Treasury yields stabilize. Gold mining stocks also decline due to dip in gold ...
UBS analyst Dan Leonard maintains 10x Genomics (NASDAQ:TXG) with a Neutral and lowers the price target from $30 to $25.